RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Neuromyelitis Optica Spectrum Disorder: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study.
Kwon Soonwook et al., Multiple sclerosis (Houndmills, Basingstoke, England) (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891509/
- 2.
DIENCEPHALIC ENCEPHALOPATHY WITH OPTIC SHEATH ENHANCEMENT AND SEVERE HYPERNATREMIA: A DIAGNOSTIC DILEMMA BETWEEN WERNICKE'S ENCEPHALOPATHY AND ATYPICAL NMOSD
, International Journal of Drug Delivery Technology (16 October 2026)
https://doi.org/10.25258/ijddt.16.70s.168
- 3.
Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry.
Tortorella Carla et al., Journal of neurology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42881253/
- 4.
Why repair fails in AQP4-IgG-positive neuromyelitis optica spectrum disease: an astrocyte-centered framework for remyelination and neuroaxonal preservation
Luo W et al. (16 October 2026)
https://europepmc.org/search?query=Why%20repair%20fails%20in%20AQP4-IgG-positive%20neuromyeliti
- 5.
Utility of Blood Neutrophil to Diagnose Bacterial Infections under Satralizumab Treatment for Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: A Report of Two Cases.
Kuroda Hiroshi et al., Internal medicine (Tokyo, Japan) (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42875202/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT04201262 · Completed · Phase 3 · Alexion Pharmaceuticals, Inc.
Ages 18 to 100
https://clinicaltrials.gov/study/NCT04201262
- 2.
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
NCT02200770 · Completed · Phase 2 / Phase 3 · MedImmune LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT02200770
- 3.
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT02003144 · Completed · Phase 3 · Alexion Pharmaceuticals, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT02003144
- 4.
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
NCT01892345 · TERMINATED · Phase 3 · Alexion Pharmaceuticals, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT01892345
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: A prodromal phase is increasingly recognized in multiple sclerosis and neuromyelitis optica spectrum disorder, but the temporal patterns of autoimmune diseases remain poorly characterized. OBJECTIVES: To evaluate the risk and timing of autoimmune diseases before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis. METHODS: Using the Korean National Health Insurance Service database (2011-2021), we identified incident multiple sclerosis (n = 3079) and neuromyelitis optica spectrum disorder (n = 1407) cases, each matched with 10 controls by age, sex, and index year. Autoimmune diseases were assessed during the 10 years preceding the index year and categorized into early (5-10 years), intermediate (2-5 years), and late (0-2 years). Adjusted rate ratios were estimated using Poisson regression. RESULTS: Autoimmune diseases occurred more frequently before the index year in multiple sclerosis (adjusted rate ratio = 1.58, 95% confidence interval = 1.46-1.71) and neuromyelitis optica spectrum disorder (adjusted rate ratio = 1.28, 95% confidence interval = 1.14-1.45) than controls, with the greatest differences in the late period. The adjusted rate ratio of autoimmune diseases in multiple sclerosis persisted across all periods, whereas the adjusted rate ratio was increased only in the intermediate and late periods in neuromyelitis optica spectrum disorder. Systemic autoimmune diseases, including systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis, were more frequent in both conditions. CONCLUSIONS: The burden of autoimmune disease is increased before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis.
Common Questions
What is Neuromyelitis Optica Spectrum Disorder?
Neuromyelitis Optica Spectrum Disorder is a rare autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord. It is frequently misdiagnosed as Multiple Sclerosis. The majority of cases involve antibodies against aquaporin-4 (AQP4) water channels. Timely diagnosis is critical as some MS treatments can worsen NMOSD.
How many clinical trials are available for Neuromyelitis Optica Spectrum Disorder?
RareWays currently indexes 101 clinical trials for Neuromyelitis Optica Spectrum Disorder, of which 21 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Neuromyelitis Optica Spectrum Disorder come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Neuromyelitis Optica Spectrum Disorder.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.